Abstract
Abstract Response to DNA-damaging agents, such as PARP inhibitors (PARPi), is associate with homologous recombination deficiency (HRD). In fact, patients with advanced breast, prostate, and ovarian cancers who carry harmful mutations in BRCA1/2 have benefited greatly from olaparib, niraparib, and rucaparib as reported in multiple clinical trials. However, current available assays either require tumor biopsy which may be of insufficient quantity or unobtainable or only examine very limited genes such as BRCA1, BRCA2, and ATM from patient blood. We recently developed a blood-based NGS panel to accurately detect genomic alterations in 51 genes related to DNA damage and repair. With in-house proprietary ultra-sensitive DeepSeaTM(Deterministic, Efficient, Precise, Sensitive Algorithm) variant detection algorithm, analytical performance was rigorously assessed via serial dilutions of reference materials and also further validated by clinical plasma samples in prostate, ovarian, lung and breast cancer. Key words: cfDNA, DNA damage repair, PARP, BRCA1, BRCA2, liquid biopsy, biomarker Citation Format: Xiaohong Wang, Jianjun Yu. Analytical and clinical validation of blood-based NGS panel for detection of genomic alterations in DNA repair pathways [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2018; 2018 Apr 14-18; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2018;78(13 Suppl):Abstract nr 5570.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.